摘要
目的 :对头孢吡肟和头孢他啶治疗中、重度肺炎的成本效用进行分析。方法 :118例中、重度肺炎病人前瞻性临床随机对照研究 ,头孢吡肟组 (n=6 0 ) ,中度感染 1g,重度感染 2 g,iv gtt,bid× 7～ 10 d;头孢他啶组 (n=5 8) ,中度感染 1g,重度感染 2 g,iv gtt,bid× 7～ 10 d。结果 :2组治疗总有效率分别为 88%和 79% ,差别无显著意义 (P>0 .0 5 )。头孢吡肟在用药过程中能够更有效地改善病人生活质量。头孢吡肟组每例可节省直接医疗费用 380 0元左右。结论 :头孢吡肟 iv gtt治疗中、重度肺炎比头孢他啶 iv gtt更具成本效果。
AIM: To evaluate the cost utility of cefepime vs ceftazidime for medium and severe pneumonia. METHODS: One hundred and eighteen patients with medium or severe pneumonia were divided into 2 groups in the prospective randomized clinical trial. Cefepime group (60 patients) received cefepime 1 g for medium pneumonia and cefepime 2 g, iv gtt, bid×7-10 d for severe pneumonia; ceftazidime group (58 patients) received ceftazidime 1 g for medium pneumonia and ceftazidime 2 g, iv gtt, bid×7-10 d for severe pneumonia. RESULTS: The total effective rates in 2 groups were 88% and 79%, respectively ( P >0 05). Cefepime was more effective in improving patients' quality of life than ceftazidime in the duration of therapy. Cefepime therapy can save about 3 800 yuan RMB per patient in the medical expenditure. CONCLUSION: Intravenous instillation of cefepime is more cost effective than ceftazidime in the treatment of patients with medium or severe pneumonia.
出处
《中国临床药学杂志》
CAS
2000年第4期237-241,共5页
Chinese Journal of Clinical Pharmacy
关键词
成本效用分析
肺炎
头孢吡肟
头孢他啶
cost utility analysis
randomized controlled trials
pneumonia
cefepime
ceftazidime
